Mondobiotech Holding AG Company presentation

Scientific Snapshot Information: DK-1000-01
§� Pulmonary Arterial Hypertension (PAH) is a debilitating and
often fatal disease which affects the small pulmonary arteries.
PAH is characterised by a de-regulated biology of cells in the lung
leading to a narrowing of the blood vessels (vasoconstriction),
vascular smooth muscle cell proliferation, remodeling, and
perivascular inflammation. As a consequence of this high
resistance, an abnormally high blood pressure is built up in the
lungs placing a strain on the right side of the heart, eventually
leading to progressive right heart failure with a fatal outcome
after a period of severe debilitation.
• Panel A shows a normal heart
• Panel B pulmonary hypertension.
• RV, right ventricle; LV, left ventricle;
• RA right atrium; LA, left atrium
• Mechanism of Action:
DK-1000 is a synthetically-produced peptide which acts via
specific G protein-coupled receptors which are present in the
lungs and peripheral tissues. These receptors are present on
thymocytes, T cells, macrophages, monocytes, endothelial cells
and vascular smooth muscle cells. DK-1000 is a potent vasodilator
which also has inhibitory effects on smooth muscle cell
proliferation, inflammation and platelet aggregation. DK-1000
has potential to provide therapeutic benefit to PAH patients by
lowering pulmonary arterial pressure, increasing cardiac output,
and reducing inflammation. Despite the broad range of drugs
which are used to treat PAH (usually in combinations) DK-1000
has the potential to provide the combined pharmacological
effects of a vasodilator and an anti-inflammatory in a
monotherapy.
§� Key data (Clinical PoC data):
In clinical PoC, inhaled DK-1000 improves
hemodynamic and prognostic parameters of PAH and leads
to an increase in the distance achieved during a 6-minute
walk test.
43